Adverse events associated with itraconazole in 189 patients on chronic therapy.
Itraconazole was administered at doses of 50-400 mg/day to 189 patients with a variety of systemic mycoses for a median of five months. Adverse reactions possibly due to itraconazole were seen in 74 patients (39%). Mild gastrointestinal reactions were most common; other reactions including hypertriglyceridaemia, hypokalaemia and liver enzyme elevations occurred less frequently. No fatal reactions have been noted and toxicity has rarely led to a discontinuation of therapy. Chronic therapy with itraconazole appears well tolerated by the majority of patients.
Tucker
R M
RM
Department of Medicine, Santa Clara Valley Medical Center, California Institute for Medical Research, San Jose 95128.
Haq
Y
Y
Denning
D W
DW
Stevens
D A
DA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D017964:Itraconazole; D007654:Ketoconazole / Q000009:adverse effects / Q000031:analogs & derivatives*; D008297:Male; D008825:Miconazole / Q000009:adverse effects; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*
D000935:Antifungal Agents; D017964:Itraconazole; D008825:Miconazole; D007654:Ketoconazole